Quince Therapeutics: Cornerstone Capital Bank Achieves Milestone in Mortgage Lending Success
- Quince Therapeutics was not mentioned in the content provided regarding Cornerstone Capital Bank’s mortgage lending achievements.
- Cornerstone's loan officers earned recognition as Scotsman Guide 2025 Top Originators, reflecting their outstanding performance.
- The bank funded over 21,000 home loans in 2024, showcasing its commitment to excellence in the mortgage industry.
Cornerstone Capital Bank Celebrates Success in Mortgage Lending
Cornerstone Capital Bank, headquartered in Houston, Texas, recently highlights a significant achievement within its residential mortgage division. Over one-third of its loan officers have earned recognition as Scotsman Guide 2025 Top Originators, an accolade that underscores their exceptional performance in the competitive mortgage lending landscape. This distinction is based on rigorous criteria, evaluating more than 5,500 loan officers and requiring a minimum of $25 million in annual funded loan volume or at least 75 closed loans. The acknowledgment not only includes loan officers from Cornerstone Home Lending but also extends to its joint venture partnerships with home builders and realty brokerages, showcasing the collaborative spirit and market impact of the bank's operations.
In 2024, Cornerstone's loan officers demonstrate remarkable productivity, funding more than 21,000 home loans, which represents more than double the number of home loans funded by their closest competitor. This impressive performance reflects a commitment to excellence and customer satisfaction in the mortgage industry. Adam Laird, CEO of Cornerstone Home Lending, emphasizes the bank's dedication to supporting its loan officers through strategic investments in resources and tools designed to enhance their business growth. Such support not only empowers the loan officers but also contributes positively to the families they serve, creating a ripple effect of financial stability and home ownership in the community.
The foundation of Cornerstone Capital Bank, formed through the 2022 merger of Cornerstone Home Lending and The Roscoe State Bank, is rooted in a legacy dating back to 1906. As Texas' highest-capitalized new bank at the time of its merger, Cornerstone now boasts a workforce of 1,500 employees and over 600,000 relationships in mortgage financing, commercial financing, and deposit accounts. The bank's commitment to creating a positive work environment is reflected in its recognition as a certified Fortune Great Place to Work® and multiple awards as a Top Workplace. This commitment not only fosters employee satisfaction but also enhances the overall customer experience.
In addition to its impressive accolades, Cornerstone Capital Bank continues to innovate in the mortgage lending space, striving to provide comprehensive banking services to meet diverse customer needs. The bank's proactive approach to business growth and community impact positions it as a leader in the financial industry, paving the way for future achievements in mortgage financing and beyond. For more information about Cornerstone Capital Bank and its offerings, visit their website at www.cornerstonecapital.com.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…